Adamas Pharmaceuticals, Inc.
https://www.adamaspharma.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Adamas Pharmaceuticals, Inc.
Supernus Adds To CNS Portfolio, Especially In Parkinson’s, With Adamas Buyout
Building upon the May 2020 acquisition of US WorldMeds, Supernus is diversifying beyond Trokendi for epilepsy and will be able to rely on its existing commercial force for CNS products.
Keeping Track: Targeted Oncologics Tepmetko, Ukoniq Cleared; Posimir Earns Opioid-Sparing Language
The latest US FDA approval news from the Pink Sheet’s US FDA Performance Tracker
Scrip Asks…What Does 2021 Hold For Biopharma? Part 3: Patient Access To Health Care
Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.
Deal Watch: Merck & Co. Looks To Advance NASH Ambitions With Aligos
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
- Other Names / Subsidiaries
-
- Osmotica Pharmaceutical US
- Supernus Pharmaceuticals, Inc.